HETLIOZ

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Poland.

Active ingredients

The drug HETLIOZ contains one active pharmaceutical ingredient (API):

1	Tasimelteon UNII SHS4PU80D9 - TASIMELTEON
	Tasimelteon is a circadian regulator that resets the master body clock in the suprachiasmatic nucleus (SCN). Tasimelteon acts as a Dual Melatonin Receptor Agonist (DMRA) with selective agonist activity at the MT1 and MT2 receptors. These receptors are thought to be involved in the control of circadian rhythms.
	Read more about Tasimelteon

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
HETLIOZ Hard capsule	MPI, EU: SmPC	European Medicines Agency (EU)
HETLIOZ Capsule	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N05CH03		N Nervous system → N05 Psycholeptics → N05C Hypnotics and sedatives → N05CH Melatonin receptor agonists
Discover more medicines within N05CH03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1691760
IT	Agenzia del Farmaco	044394017
LT	Valstybinė vaistų kontrolės tarnyba	1077353
PL	Rejestru Produktów Leczniczych	100351334
US	FDA, National Drug Code	43068-220